Home
Live Updates
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress : comparemela.com
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...
Related Keywords
Beijing ,
China ,
Spain ,
Tianjin ,
Shanghai ,
Oslo ,
Norway ,
Wuhan ,
Hubei ,
Ying Qian ,
Jiangxi ,
Valencia ,
Carabobo ,
Venezuela ,
Cheng Mei ,
Guangdong ,
Peking ,
Hong Kong ,
Tongji ,
Sichuan ,
Texas ,
United States ,
Houston ,
Madrid ,
Huazhong ,
Chinese ,
Renchi Yang ,
Pau Montesinos ,
Zhou Yi ,
Atholl Tweedie ,
Mingci Cai ,
Hall Mallo ,
Xiaojun Huang ,
Fengkui Zhang ,
Xiaofan Liu ,
Ben Atwell Alex Shaw ,
Waleed Ghanima ,
Tongji Medical College ,
Shanghai Jiao Tong University School Of Medicine ,
European Hematology Association ,
Linkedin ,
Nasdaq ,
Chinese Academy Of Medical Sciences ,
China Limited ,
University People Hospital ,
Union Hospital ,
Huazhong University Of Science ,
Institute Of Hematology ,
University Of Oslo ,
Stock Exchange Of Hong Kong ,
Exchange Commission ,
University Of Texas Md Anderson Cancer Center ,
Hybrid Congress ,
Immune Thrombocytopenia ,
Syk Inhibitor Sovleplenib ,
Adult Patients ,
Primary Immune Thrombocytopenia ,
Placebo Controlled Phase ,
Blood Diseases Hospital ,
Chinese Academy ,
Medical Sciences ,
Warm Antibody Autoimmune Hemolytic Anemia ,
Prior Lines ,
Subgroup Analysis ,
Huazhong University ,
Heavily Pre Treated Hodgkin Lymphoma ,
Cancer Center ,
Final Result ,
Dose Expansion ,
University People ,
Advanced Acute Myeloid Leukemia ,
Isocitrate Dehydrogenase ,
Preliminary Results ,
Dose Escalation ,
Shanghai Jiao Tong University School ,
Escalation Study ,
Third Generation ,
Highly Selective ,
Chinese Patients ,
Preliminary Efficacy ,
Syk Inhibitor ,
Adult Subjects ,
Securities Litigation Reform Act ,
Stock Exchange ,
Hong Kong Limited ,
Alex Shaw ,
comparemela.com © 2020. All Rights Reserved.